Genmab — August 2018
-
Interessant at MorPhoSys vil prøve MOR202 i en ikke-oncology indication https://seekingalpha.com/article/4193975-morphosys-ag-mpsyy-ceo-simon-moroney-q2-2018-results-earnings-call-transcript?part=single
-
MAIA er venter og det er også ventet at vi engang når et salg på 10B usd. Dagens kurs reflektere hverken MAIA eller salg på 10B usd efter min bedste overbevisning. MAIA er en meget vigtig milepæl for at kunne opnå salg på 10 B USD så mon ikke vi ser en pæn stigning i.f.m data.
-
Der er kommet yderligere to locations til i NSCLC-studiet med DuoBody EGFR x cMET (dog "not yet recruiting"). https://clinicaltrials.gov/ct2/history/NCT02609776?A=24&B=25&C=Side-by-Side
-
After nine weeks on the Darzalex, my M-protein level continues to plummet: https://viraltopfeeds.com/health-update/
-
Jeg faldt over lidt historie om Genmab's næste IND, DuoBody-CD40x4-1BB. 50/50 med Biontech. Genmab siger IND i 2018 og Biontech siger 2019 for first in human. http://www.iact-project.eu/IACT_consortium.htm
-
God morgen

-
God morgen

Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind